

Survey of follow-up catheterization use in pediatric pulmonary hypertension - a TOPP-2 registry analysis

Kanaan U^{1,2}, Ivy D³, Berger RMF⁴, Humpl T⁵, Bonnet D⁶, Bowers D⁷, Mariotti Nesurini S⁸, Beghetti M⁹
on behalf of the TOPP-2 registry investigators

¹Children's Healthcare of Atlanta, Atlanta, Georgia; ²Emory University, Atlanta, Georgia; ³Children's Hospital Colorado, Aurora, Colorado; ⁴Beatrix Children's Hospital, Groningen, the Netherlands; ⁵The Hospital for Sick Children University of Toronto, Toronto, Ontario, Canada; ⁶M3C-Necker Hospital for Sick Children, Paris, France; ⁷University of Suffolk, Ipswich, United Kingdom; ⁸nspm Ltd, Meggen, Switzerland; ⁹Children's University Hospital and University of Geneva, Geneva, Switzerland

Background



- Initial right heart catheterization (RHC) is the gold standard for diagnosis of pulmonary hypertension (PH)
- The role of follow-up RHC (FURHC) is less clear
- We sought to describe institutional practice regarding FURHC practice among pediatric PH centers participating in the Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension-2 (TOPP-2) registry (NCT02610660)

Methods


- REDCap-based survey of pediatric centers participating in the TOPP-2 registry performed in 2021

Results - participating centers

- 30 of 31 centers responded





Key finding:
There is substantial variability in institutional practice among pediatric pulmonary hypertension centers regarding the use of follow-up right heart catheterization




Location of centers participating in the TOPP-2 registry

Contact Info: kanaanu@kidsheart.com

Results - use of routine FURHC



Results - use of clinically indicated FURHC



Conclusions

- There is wide variability in clinical practice regarding the indications for and timing of FURHC in pediatric PH
- Further research should clarify the clinical utility of this invasive test to inform practice guidelines

Disclosures

- The TOPP-2 registry was supported by an unrestricted research grant from Actelion/Janssen Pharmaceuticals Ltd.